A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Grade Serous Ovarian Cancer

Interventions

DRUG: avutometinib
DRUG: Defactinib
DRUG: Pegylated liposomal doxorubicin
DRUG: Paclitaxel
DRUG: Letrozole
DRUG: Anastrozole

Sponsor

Verastem, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]